JUNG KIM: Open Payments
NPI 1699239293 · MIDLOTHIAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,164 in 95 payments from 20 companies in 2025. Trend: 2023 $1,298 · 2024 $1,460 · 2025 $2,164
Food & beverage: $2,164
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $674 |
| Vanda Pharmaceuticals Inc. | 12 | $338 |
| Novo Nordisk Inc | 10 | $183 |
| PFIZER INC. | 11 | $166 |
| Otsuka America Pharmaceutical, Inc. | 3 | $141 |
| Xeris Pharmaceuticals, Inc. | 4 | $103 |
| Lilly USA, LLC | 5 | $85 |
| Axsome Therapeutics, Inc. | 4 | $83 |
| KYOWA KIRIN, INC. | 3 | $73 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $67 |
Products named: VRAYLAR, FANAPT, NURTEC ODT, REXULTI, QULIPTA, Ozempic, Symbravo, CRYSVITA.
Industry payments across VA — which companies pay providers there.
